Inclusion Criteria:

          -  Must be appropriate candidate for experimental therapy, as determined by investigator,
             after available standard therapies have failed

          -  Have adequate organ function

          -  Prior Therapies: Systemic treatments: must have discontinued previous systemic
             treatments for cancer and recovered from the acute effects of therapy. Participants
             must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have
             discontinued any cytotoxic therapies at least 28 days prior to study enrollment.
             Radiation therapy and surgery: must be completed at least 4 weeks before study
             enrollment

          -  All parts except Part B, Part E2, and Part E3 dose expansion: Must have diagnosis of
             cancer that is advanced or metastatic

          -  Part B dose expansion: Must have confirmed Kirsten rat sarcoma viral oncogene homolog
             (KRAS) wild-type colorectal cancer that is metastatic or recurrent and has failed
             oxaliplatin- and irinotecan-based chemotherapy or who are intolerant of irinotecan or
             oxaliplatin

          -  Part E2 dose expansion: must have cancer that is advanced or metastatic and have prior
             documentation of a mutation of PIK3CA

          -  Part E3 dose expansion: must have advanced or metastatic ER-negative, PR-negative, and
             HER-2 non-overexpressing breast cancer

          -  Must be available during the duration of the study and willing to follow the study
             procedures

          -  Parts A and B: If participant is of reproductive potential, must agree to use
             medically approved contraceptive precautions during the study and for six months
             following the last dose of study drug

          -  Parts C, D and E: If participant is of reproductive potential, must agree to use
             medically approved contraceptive precautions during the study and for three months
             following the last dose of study drug

          -  If the participant is a female of childbearing potential, must have had a negative
             serum or urine pregnancy test within 14 days of the first dose of study drug and must
             not be breast feeding

          -  Part E: Are able to swallow capsules or tablets

        Exclusion Criteria:

          -  Have received more than 2 previous lines of cytotoxic chemotherapy (if receiving
             cisplatin, 5-FU or pemetrexed)

          -  Must not have taken an unapproved drug as treatment for any indication within the last
             28 days prior to starting study treatment

          -  Must not have an active symptomatic fungal, bacterial or viral infection, including
             human immunodeficiency virus (HIV) or Hepatitis A, B, or C

          -  Must not have a serious heart condition, such as congestive heart failure, unstable
             angina pectoris, or heart attack within the last three months

          -  Must not have a family history of long QTc syndrome

          -  Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced
             serotonin syndrome

          -  Must not have acute leukemia

          -  Part E: Have insulin-dependent (type I) diabetes or a history of gestational diabetes

          -  Part E: Prior treatment with a PI3K/mTOR inhibitor